Researchers developed a biomimetic nanovesicle that crosses the blood-brain barrier, degrades DNA repair proteins, and ...

Lantern Pharma Inc. , an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary AI platform, RADR®, today announced that it has received ...

A phase 1b/2 trial in triple-negative breast cancer will assess LP-184 alone and with a PARP inhibitor in advanced cases.

Researchers found that flight attendants show reduced DNA repair capacity and immune changes after air travel, which may help ...

One possible explanation for the gap is the availability of highly efficacious CAR-T therapies in the U.S. and Europe serving as later-line therapies to improve survival outcomes. The FDA has also ...

Novel RBM39 molecular glue achieves complete tumor regression in mechanism-based Ewing sarcoma models; IND filing expected ...

Companies including AstraZeneca and Merck KGaA are studying forms of synthetic lethality beyond the homologous recombination deficiency pathway targeted by PARP drugs. Tessellate has found a ...

The mitochondrion plays critical roles in cellular function, making it a prime organelle to target for fundamental studies, ...

Secondly, if the same sequences are used often, particularly in metabolic engineering, it can actually lead to homologous recombination and then genetic instability. So ideally, there would be a ...

Lantern Pharma's LP-184 advances to Phase 1b/2 trial in TNBC after FDA clearance, adding to its Fast Track and Rare Pediatric Disease designations.

LTRN A May 5th press release indicated that the FDA cleared Lantern Pharma, Inc.’s (NASDAQ:LTRN) LP-184 trial in triple ...